Sakar Healthcare Limited has informed the Exchange about SAKAR granted with the SECOND Marketing Authorization (MA)/ Registration of ONCOLOGY INJECTION in the EUROPEAN UNION (EU)
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.3 pts more than Nifty Microcap 250 and 10.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sakar Healthcare has received its second Marketing Authorization (MA) for an oncology injection in the European Union, following the first approval in April 2025. While the first approved product treats breast, lung, and prostate cancer, this new approval is specifically for treating colorectal cancer, a widely prevalent cancer type. The first MA is already in the process of its first commercial supply to Europe, and more products including liquid injections, lyophilised injections, and oral solids are currently under EU registration, with approvals expected in coming months. The company operates an EU GMP approved, vertically integrated oncology manufacturing facility. This second approval strategically broadens the company's ability to export and commercialise oncology injectable products across European markets.
This is a positive development for shareholders as it strengthens Sakar's export pipeline to a regulated, high-value market (EU) and expands the addressable oncology product portfolio. However, near-term stock impact may be limited until actual commercial revenues from these approvals start materialising, as approvals alone do not immediately translate to large orders.